Jefferies analyst Biren Amin reiterated a Buy rating on AnaptysBio Inc (NASDAQ: ANAB) yesterday and set a price target of $121. The company’s shares closed yesterday at $81.90.
According to TipRanks.com, Amin is a 5-star analyst with an average return of 16.1% and a 53.7% success rate. Amin covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Armo Biosciences Inc, and Heron Therapeutics.
AnaptysBio Inc has an analyst consensus of Strong Buy, with a price target consensus of $133.
See today’s analyst top recommended stocks >>
Based on AnaptysBio Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $15.09 million. In comparison, last year the company earned revenue of $7 million and had a GAAP net loss of $2.68 million.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ANAB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies.
